Clinuvel Pharmaceuticals' drug SCENESSE® (afamelanotide) has received Health Canada's Notice of Compliance for preventing phototoxicity in adults with erythropoietic protoporphyria (EPP), a rare metabolic disorder causing severe skin reactions to light. This approval allows Clinuvel to market SCENESSE® in Canada, joining previous approvals in Europe, the US, and Australia. SCENESSE® is the only approved systemic treatment for EPP, with a proven long-term safety profile backed by over 21,000 doses administered globally. The drug works by increasing melanin production to protect skin from light damage, offering significant benefit to patients with limited treatment options.
Ledger identified and patched a vulnerability in its Ethereum application that could allow malicious apps to alter transaction data during user review. The fix was deployed about two weeks before a security company publicly disclosed the issue. Ledge...
The Ethereum Foundation is sponsoring the WPPT 2026 workshop in Hong Kong, focusing on privacy-preserving technologies in blockchain. This move highlights the foundation's strategic emphasis on zero-knowledge proofs and enhancing protocol privacy. Su...
A Federal Reserve Bank of Cleveland study shows that sharing Bitcoin's past gains increases how much cryptocurrency U.S. households want to own and their likelihood of buying it. Crypto owners expect much higher returns than nonowners, and exposure t...
Ethena (ENA) experienced a significant breakout above its $0.14 resistance, reaching $0.1707, driven by strong buying momentum. A $1.5 million whale deposit of 9.776 million ENA tokens into Binance introduced supply pressure, but was counterbalanced ...
Tether CEO Paolo Ardoino highlighted growing reliance on the USDT stablecoin in countries like Venezuela, Argentina, Bolivia, and Turkey due to inflation, currency depreciation, and limited access to physical dollars. These economies use USDT for dom...
